Scientists to Present Data and Discuss Emerging Advances in Basic Research
and Clinical Science at Neuroscience 2007 Satellite Symposium
ABBOTT PARK, Ill., Nov. 1 /PRNewswire-FirstCall/ -- The human brain relies on chemicals called "neurotransmitters" that nerve cells use to communicate to one another, in order to maintain a wide range of cognitive functions including memory and attention. Based on a growing body of scientific knowledge related to neurotransmitters, the scientific community is now targeting neuronal nicotinic receptors (NNRs), found on nerve cells throughout the central nervous system, to treat a number of psychiatric and neurological disorders. NNRs, also known as neuronal nicotinic acetylcholine receptors (nAChRs), modulate the release of several important neurotransmitters, such as acetylcholine and dopamine.
Abbott researchers are currently developing selective NNR compounds, which act as agonists (drugs that stimulate activity at cell receptors) at specific NNR sites in the body, for attention-deficit hyperactivity disorder, Alzheimer's disease, schizophrenia and pain -- conditions for which there are still significant unmet needs in spite of available treatment options. Scientists from independent academic institutions and Abbott will present data on these compounds at the Neuroscience 2007 satellite symposium entitled "Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science." The meeting takes place Oct. 31 to Nov. 2 at the San Diego Convention Center, preceding the annual meeting of the Society for Neuroscience.
Presentations highlighting Abbott compounds include the following:
Integrative Pharmacology of nAChRs and nAChR Ligands
Bryan F. Cox, Abbott (Thursday, Nov. 1, 8 a.m.)
Preclinical and Clinical Studies with Novel nAChR Ligands in Pain
Michael D. Meyer, Abbott (Thursday, Nov. 1, 2:10 p.m.)
ADHD Overview, Preclini
Copyright©2007 PR Newswire.
All rights reserved